Obesity therapeutics: The end of the beginning.
Sign Up to like & getrecommendations! Published in 2021 at "Cell metabolism"
DOI: 10.1016/j.cmet.2021.03.012
Abstract: Obese non-diabetic patients receiving semaglutide, an injectable long-acting GLP-1 receptor agonist, in a large randomized placebo-controlled trial, lost and maintained ∼15% of their body weight for over a year (Wilding et al., 2021). This impressive result… read more here.
Keywords: therapeutics end; obesity; end beginning; obesity therapeutics ... See more keywords